Crystal engineering has been identified by pharmaceutical scientists as a means of improving and tailoring the physicochemical properties of active pharmaceutical ingredients (API). The properties of an API may be modified through salt formation using a limited number of available counter ions. Co-crystals offer further potential for changing the API properties by using a much more extensive range of co-crystallizing molecules (co-builders). A pharmaceutical co-crystal contains API with excipients or other APIs. It is important to note that co-crystals are a homogeneous phase of stoichiometric composition and not a mixture of pure component crystalline phases. Co-crystals possess tremendous uplifting properties compared to normal crystals like enhancement of bio-availability, solubility19, stability. The present article deals with various aspects of co-crystal fabrication, pharmaceutical application, and various patented technologies related to co-crystallization.